Found: 30
Select item for more details and to access through your institution.
The biological function of IGF2BPs and their role in tumorigenesis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1682, doi. 10.1007/s10637-021-01148-9
- By:
- Publication type:
- Article
IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1538, doi. 10.1007/s10637-021-01160-z
- By:
- Publication type:
- Article
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1457, doi. 10.1007/s10637-021-01151-0
- By:
- Publication type:
- Article
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1694, doi. 10.1007/s10637-021-01150-1
- By:
- Publication type:
- Article
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1641, doi. 10.1007/s10637-021-01152-z
- By:
- Publication type:
- Article
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1633, doi. 10.1007/s10637-021-01149-8
- By:
- Publication type:
- Article
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1598, doi. 10.1007/s10637-021-01147-w
- By:
- Publication type:
- Article
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1613, doi. 10.1007/s10637-021-01146-x
- By:
- Publication type:
- Article
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1604, doi. 10.1007/s10637-021-01145-y
- By:
- Publication type:
- Article
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1587, doi. 10.1007/s10637-021-01141-2
- By:
- Publication type:
- Article
Serine hydroxymethyltransferase 2: a novel target for human cancer therapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1671, doi. 10.1007/s10637-021-01144-z
- By:
- Publication type:
- Article
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1732, doi. 10.1007/s10637-021-01140-3
- By:
- Publication type:
- Article
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1724, doi. 10.1007/s10637-021-01139-w
- By:
- Publication type:
- Article
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1577, doi. 10.1007/s10637-021-01138-x
- By:
- Publication type:
- Article
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1523, doi. 10.1007/s10637-021-01137-y
- By:
- Publication type:
- Article
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1716, doi. 10.1007/s10637-021-01136-z
- By:
- Publication type:
- Article
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1702, doi. 10.1007/s10637-021-01135-0
- By:
- Publication type:
- Article
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1656, doi. 10.1007/s10637-021-01134-1
- By:
- Publication type:
- Article
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1549, doi. 10.1007/s10637-021-01133-2
- By:
- Publication type:
- Article
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1493, doi. 10.1007/s10637-021-01132-3
- By:
- Publication type:
- Article
Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1707, doi. 10.1007/s10637-021-01131-4
- By:
- Publication type:
- Article
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1664, doi. 10.1007/s10637-021-01130-5
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1568, doi. 10.1007/s10637-021-01120-7
- By:
- Publication type:
- Article
Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1469, doi. 10.1007/s10637-021-01128-z
- By:
- Publication type:
- Article
Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1460, doi. 10.1007/s10637-021-01127-0
- By:
- Publication type:
- Article
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1649, doi. 10.1007/s10637-021-01125-2
- By:
- Publication type:
- Article
Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1484, doi. 10.1007/s10637-021-01129-y
- By:
- Publication type:
- Article
Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1559, doi. 10.1007/s10637-021-01107-4
- By:
- Publication type:
- Article
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1624, doi. 10.1007/s10637-021-01078-6
- By:
- Publication type:
- Article
Development and validation of a ferroptosis-related prognostic model in pancreatic cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1507, doi. 10.1007/s10637-021-01114-5
- By:
- Publication type:
- Article